Immuron (IMRN) Research & Development (2016 - 2024)
Immuron (IMRN) posted quarterly Research & Development of -$1296.2 billion for Q4 2024, down 48857378.76% year-over-year from N/an in Q1 2024, and down 48857378.76% quarter-over-quarter from -$2.7 million in Q4 2023.
Immuron (IMRN) Research & Development (2016 - 2024) Analysis & Trends
Immuron's Research & Development history runs 9 years deep, the most recent figure standing at -$1296.2 billion for Q4 2024.
- In Q4 2024, Research & Development fell 48857378.76% year-over-year to -$1296.2 billion; the TTM figure through Dec 2024 stood at -$1296.2 billion (down 31922477.45% YoY), while the FY2025 annual figure was $2.3 million, down 33.87% from the prior year.
- Research & Development for Q4 2024 stood at -$1296.2 billion, down from -$2.7 million in the prior quarter.
- The five-year high for Research & Development was $358281.0 in Q4 2020, with the low at -$1296.2 billion in Q4 2024.
- The 5-year median for Research & Development is -$834870.8 (2022), against an average of -$216.0 billion.
- The sharpest annual moves came in 2021 and 2024: Research & Development retreated 26.8% in 2021, then plunged 48857378.76% in 2024.
- Immuron's Research & Development stood at $358281.0 in 2020, then declined by 26.8% to $262268.2 in 2021, then tumbled by 680.18% to -$1.5 million in 2022, then sank by 74.36% to -$2.7 million in 2023, then slumped by 48857378.76% to -$1296.2 billion in 2024.
- Business Quant data shows IMRN's Research & Development at -$1296.2 billion in Q4 2024, -$2.7 million in Q4 2023, and -$148106.7 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 97.90 Mn |
| 10 | Immuron | 6.64 Mn | 6.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1,296.23 Bn |
| Dec 31, 2023 | -2.65 Mn |
| Jun 30, 2023 | -148,106.67 |
| Dec 31, 2022 | -1.52 Mn |
| Dec 31, 2021 | 262,268.17 |
| Dec 31, 2020 | 358,281.00 |
| Dec 31, 2019 | 531,828.00 |
| Dec 31, 2018 | 1.19 Mn |
| Dec 31, 2017 | -1.20 Mn |
| Dec 31, 2016 | -1.60 Mn |
| Jun 30, 2016 | -2.71 Mn |